BACKGROUND: Combined inhibition of epidermal growth factor receptor (EGFR) and Src family kinases (SFK) may lead to improved therapeutic effects. We evaluated the combination of dasatinib, an inhibitor of SFK and other kinases, and cetuximab, an anti-EGFR monoclonal antibody. PATIENTS AND METHODS: Patients with advanced solid malignancies received cetuximab intravenously on a standard weekly schedule and dasatinib orally, once daily at 3 dose levels: (1) 100 mg, (2) 150 mg, (3) 200 mg. Pharmacokinetic and pharmacodynamic studies of dasatinib were performed prior to starting cetuximab and following 14 days of treatment. RESULTS: Twenty-five patients (3 dose level 1; 19 dose level 2; 3 dose level 3) were initially treated. Three patients developed dose-limiting toxicities: 1 at dose level 2 (headache) and 2 at dose level 3 (headache, nausea). Grade 3-4 toxicities in more than 2 patients included: dyspnea (4), vomiting (4), nausea (3), hypersensitivity reactions (3), headache (3) and anemia (3). Twenty-one patients developed headache (8 grade 1; 10 grade 2), which occurred after the loading of cetuximab and lasted 1-3 days. Six additional patients were treated with dasatinib starting 3 days after the loading dose of cetuximab; none developed headache after dasatinib. Dasatinib pharmacokinetics and a transient decrease in SFK PY416 levels in peripheral blood mononuclear cells were not altered by cetuximab. Patients with higher plasma TGF-alpha levels had worse progression-free survival. CONCLUSIONS: Dasatinib 150 mg once daily plus weekly cetuximab is recommended for phase II studies. Early-onset headache was ameliorated by starting dasatinib after cetuximab.
BACKGROUND: Combined inhibition of epidermal growth factor receptor (EGFR) and Src family kinases (SFK) may lead to improved therapeutic effects. We evaluated the combination of dasatinib, an inhibitor of SFK and other kinases, and cetuximab, an anti-EGFR monoclonal antibody. PATIENTS AND METHODS: Patients with advanced solid malignancies received cetuximab intravenously on a standard weekly schedule and dasatinib orally, once daily at 3 dose levels: (1) 100 mg, (2) 150 mg, (3) 200 mg. Pharmacokinetic and pharmacodynamic studies of dasatinib were performed prior to starting cetuximab and following 14 days of treatment. RESULTS: Twenty-five patients (3 dose level 1; 19 dose level 2; 3 dose level 3) were initially treated. Three patients developed dose-limiting toxicities: 1 at dose level 2 (headache) and 2 at dose level 3 (headache, nausea). Grade 3-4 toxicities in more than 2 patients included: dyspnea (4), vomiting (4), nausea (3), hypersensitivity reactions (3), headache (3) and anemia (3). Twenty-one patients developed headache (8 grade 1; 10 grade 2), which occurred after the loading of cetuximab and lasted 1-3 days. Six additional patients were treated with dasatinib starting 3 days after the loading dose of cetuximab; none developed headache after dasatinib. Dasatinib pharmacokinetics and a transient decrease in SFK PY416 levels in peripheral blood mononuclear cells were not altered by cetuximab. Patients with higher plasma TGF-alpha levels had worse progression-free survival. CONCLUSIONS:Dasatinib 150 mg once daily plus weekly cetuximab is recommended for phase II studies. Early-onset headache was ameliorated by starting dasatinib after cetuximab.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Louis J Lombardo; Francis Y Lee; Ping Chen; Derek Norris; Joel C Barrish; Kamelia Behnia; Stephen Castaneda; Lyndon A M Cornelius; Jagabandhu Das; Arthur M Doweyko; Craig Fairchild; John T Hunt; Ivan Inigo; Kathy Johnston; Amrita Kamath; David Kan; Herbert Klei; Punit Marathe; Suhong Pang; Russell Peterson; Sidney Pitt; Gary L Schieven; Robert J Schmidt; John Tokarski; Mei-Li Wen; John Wityak; Robert M Borzilleri Journal: J Med Chem Date: 2004-12-30 Impact factor: 7.446
Authors: Priya Koppikar; Seung-Ho Choi; Ann Marie Egloff; Quan Cai; Shinsuke Suzuki; Maria Freilino; Hiroshi Nozawa; Sufi M Thomas; William E Gooding; Jill M Siegfried; Jennifer R Grandis Journal: Clin Cancer Res Date: 2008-07-01 Impact factor: 12.531
Authors: Jiannong Li; Uwe Rix; Bin Fang; Yun Bai; Arthur Edwards; Jacques Colinge; Keiryn L Bennett; Jingchun Gao; Lanxi Song; Steven Eschrich; Giulio Superti-Furga; John Koomen; Eric B Haura Journal: Nat Chem Biol Date: 2010-02-28 Impact factor: 15.040
Authors: Anthony J Mutsaers; Giulio Francia; Shan Man; Christina R Lee; John M L Ebos; Yan Wu; Larry Witte; Scott Berry; Malcolm Moore; Robert S Kerbel Journal: Clin Cancer Res Date: 2009-03-10 Impact factor: 12.531
Authors: Qing Zhang; Sufi M Thomas; Sichuan Xi; Thomas E Smithgall; Jill M Siegfried; Joanne Kamens; William E Gooding; Jennifer Rubin Grandis Journal: Cancer Res Date: 2004-09-01 Impact factor: 12.701
Authors: Niharika B Mettu; Donna Niedzwiecki; Christel Rushing; Andrew B Nixon; Jingquan Jia; Sherri Haley; Wanda Honeycutt; Herbert Hurwitz; Johanna C Bendell; Hope Uronis Journal: Cancer Chemother Pharmacol Date: 2019-03-20 Impact factor: 3.333
Authors: A Argiris; A P Kotsakis; T Hoang; F P Worden; P Savvides; M K Gibson; R Gyanchandani; G R Blumenschein; H X Chen; J R Grandis; P M Harari; M S Kies; S Kim Journal: Ann Oncol Date: 2012-08-16 Impact factor: 32.976
Authors: L P Stabile; A M Egloff; M K Gibson; W E Gooding; J Ohr; P Zhou; N J Rothenberger; L Wang; J L Geiger; J T Flaherty; J R Grandis; J E Bauman Journal: Oral Oncol Date: 2017-04-09 Impact factor: 5.337
Authors: Julie E Bauman; Umamaheswar Duvvuri; William E Gooding; Tanya J Rath; Neil D Gross; John Song; Antonio Jimeno; Wendell G Yarbrough; Faye M Johnson; Lin Wang; Simion Chiosea; Malabika Sen; Jason Kass; Jonas T Johnson; Robert L Ferris; Seungwon Kim; Fred R Hirsch; Kimberly Ellison; John T Flaherty; Gordon B Mills; Jennifer R Grandis Journal: JCI Insight Date: 2017-03-23